Sandbox vidit: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 22: | Line 22: | ||
{{familytree | | | |!| | | | | | | G01 | | | | | | | |G01=<div style="float: left; text-align: left; width:28em;padding:1em "> ❑ Attempt conversion as shown in table below: <br> | {{familytree | | | |!| | | | | | | G01 | | | | | | | |G01=<div style="float: left; text-align: left; width:28em;padding:1em "> ❑ Attempt conversion as shown in table below: <br> | ||
<table class="wikitable"> | <table class="wikitable"> | ||
<tr><td>▸ '''''Conversion'''''</td><td>▸ '''''Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])'''''<br> or <br>▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''<br> or <br>▸ '''''Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])'''''<br> or <br> | <tr><td>▸ '''''Conversion'''''</td><td>▸ '''''Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])'''''<br> or <br>▸ '''''DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])'''''<br> or <br>▸ '''''Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])'''''<br> or <br> '''''Flecainide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br> '''''Propafenone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br> '''''Sotalol ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])'''''<br> or <br> '''''Procainamide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]])'''''<br> or <br> '''''Amiodarone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])''''' </td></tr> | ||
</table> </div> }} | </table> </div> }} | ||
{{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }} | {{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }} |
Revision as of 15:18, 12 March 2014
Therapeutic Approach
Shown below is an algorithm summarizing the therapeutic approach to atrial flutter.[1]
Atrial flutter | |||||||||||||||||||||||||||||||||||||||||||||||
Unstable | Stable | ||||||||||||||||||||||||||||||||||||||||||||||
❑ Look for the presence of any of these:
| ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours Rate control therapy as shown in table below:
| ||||||||||||||||||||||||||||||||||||||||||||||
❑ Attempt conversion as shown in table below:
| |||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess need for therapy to prevent recurrence | |||||||||||||||||||||||||||||||||||||||||||||||
❑ Administer antiarrythmic therapy to prevent recurrences as shown below:
❑ Consider catheter ablation if antiarrhythmic therapy fails | |||||||||||||||||||||||||||||||||||||||||||||||
- ↑ "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.